Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps

• DOI: 10.1111/all.16519
• Publication Date: 2025-03-06T03:00:16Z
• Authors: Mu Xian; Bing Yan; Xicheng Song; Jianjun Chen; Jun Tang; Yan Jiang; Lijia Wan; Wen Liu; Jinmei Xue; Zhiwei Cao; Yafeng Yu; Xiangli Yang; Li Shi; Guangke Wang; Yu Xu; Yucheng Yang; Jing Ye; Luyun Jiang; Fang Quan; Guolin Tan; Feng Liu; Zhendong Xu; Xiaowen Zhang; Jiping Li; Lizhong Su; Yi Yang; Jiangang Fan; Gang He; Li Zhu; Xiangdong Wang; Ming Wang; Shen Shen; Jian Li; Huabin Li; Xin Wei; Hongmeng Yu; Zheng Liu; Ruixia Ma; Huanhai Liu; Jianfeng Liu; Wei Lv; Qintai Yang; Dongdong Zhu; Lei Cheng; Chengshuo Wang; Luo Zhang
• Keywords: Rhinology; Nasal Polyps; Position paper

Emerging biologics that selectively target key cytokines present a promising therapeutic alternative for patients suffering from severe, uncontrollable chronic rhinosinusitis with nasal polyps (CRSwNP). Despite the limited availability of registered CRSwNP treatment in China, country is experiencing rapid development this field. It imperative to standardize application biologic agents management preparation their future integration into care pathway. The Rhinology Group, Chinese Society Otorhinolaryngology-Head and Neck Surgery; Medical Doctor Association Nasal Ocular Allergy have convened an expert panel consisting principal investigators experienced clinical trials CRSwNP. This was assembled discuss China. Additionally, latest findings on pathogenesis CRSwNP, mechanisms agents, efficacy safety were reviewed, special emphasis research evidence reached consensus several critical issues, including criteria prescription, course, evaluation perspective. position paper aims guide physicians use As our experience continues grow, will be further updated.